



## **In-Cell-Art's co-founder invited to present at the SF Nano Summer School on June 7-9<sup>th</sup> 2017, dedicated to Nucleic acids-based strategies to control gene expression.**

**Nantes – France, 1<sup>st</sup> of June, 2017** – In-Cell-Art (ICA), a biotechnology company specializing in nanocarrier technologies named Nanotaxi® for unlocking the promise of nucleic acids to treat acquired or inherited diseases, announces today the participation of Dr Bruno Pitard as invited speaker at the SF Nano Summer school in La Grande Motte on 7<sup>th</sup> and 9<sup>th</sup> of June 2017. The focus of the conference is on the Nucleic Acids-based strategies to control gene expression: Principles, applications in biology, clinical translation and delivery issues.

The presentation of key scientific results in this conference where leading international researchers from renowned academic institutions and pharmaceutical companies from Germany, USA, UK, Italy Sweden, France... will participate reflects on our expertise to develop new classes of vaccines and therapies using Nucleic acids molecules delivered by Nanotaxi® in a controlled manner. During this conference, results which have been accumulated over 20 years of research, on the breakthrough discovery and development of bioinspired controlled delivery systems for mRNA vaccines and medicines will be presented.

### **About In-Cell-Art**

In-Cell-Art (ICA), which is headquartered in Nantes (France) is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of nanocarriers named Nanotaxi ® for macromolecular drugs. Its founder and research team, which includes a Nobel Laureate, have designed new classes of vectors that are organized on a nanometric scale, which enables them to cross the cell barrier efficiently and safely. In-Cell-Art offers a range of reagents and biotechnology development services:

#### **1. ICANTibodies™**

In the absence of recombinant antigen, ICANTibodies™ allows, from an in silico DNA antigenic sequence, the production of the most ambitious functional antibodies against any natively expressed nuclear, cytoplasmic, secreted or membrane proteins. ICANTibodies™ has allowed, in less than 3 years, the production of more than 300 different functional antibodies. In-Cell-Art has worked with a number of pharmaceutical firms (Sanofi, GlaxoSmithKline, Geneuro etc.) and public research institutions and universities (Institut Cochin, Cancer Research UK, Institute of Neurology UK etc).

## **2. ICA Nanotaxi®**

- DNA Vaccine

ICA614 Nanotaxi®, an innovative DNA synthetic formulation, offers unique efficient and industrial features such as the dramatic enhancement of the immunogenicity of plasmid DNA-encoding tumours or pathogen-derived antigens, a reduction in the dose of plasmid DNA, as well as an excellent safety profile. ICA614 Nanotaxi® represents a crucial step in DNA vaccine development, and is currently being tested by major vaccine companies.

- mRNA Vaccine

Some other ICA Nanotaxi® are also being assessed in \$33.1 million RN-ARMORVAX consortium, co-funded by US Defense Advanced Research Projects Agency (DARPA). The consortium would validate the new application of ICA Nanotaxi® for mRNA-based vaccines for infectious diseases in collaboration with CureVac and Sanofi-Pasteur.

- mRNA Replacement Therapy

Some other ICA Nanotaxi® are also developed to improve the limited efficacy and stability of mRNA therapeutics, leading to the dramatic increase in therapeutic protein expression without DNA-encoded gene.

## **3. ICAFectin® transfection reagents**

ICAFectin® transfection reagents are innovative breakthrough synthetic vectors for in vitro nucleic acid delivery. They are becoming the reagents of choice for efficient DNA and siRNA transfections as demonstrated by their increasing use in numerous studies published in high impact factor journals including Journal of Biological Chemistry, Nucleic Acids Research, PLOS ONE, PLOS Pathogen, Human Gene Therapy, Cell reports, EMBO Jand more.

In-Cell-Art is a privately held company, which was founded in 2005. It is a member of the Atlanpole Biotherapies high-tech cluster of biotechnology companies in western France.

For further information please contact;

In-Cell-Art

Tel: 33 (0)6 73 19 12 02

E-mail: [info@incellart.com](mailto:info@incellart.com)

Website : <http://www.incellart.com>